Access Bio Inc.

65 Clyde Rd., Suite A, 08873 Somerset, NJ
United States of America

Telephone +1 732 873-4040
Fax +1 732 873-4043


Hall map

MEDICA 2016 hall map (Hall 3): stand J46

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.15  Rapid tests - Immunochemistry

Our products

Product category: Rapid tests - Immunochemistry

CareStart™ G6PD RDT*

G6PD deficiency

G6PD deficiency is a genetic disorder, resulting in no or low G6PD activity. People with G6PD deficiency should not take primaquine, an antimalarial drug, and other drugs with high oxidative stress because it could cause serious side effects such as acute hemolysis.
Features & Benefits

True Point-Of-Care Test for G6PD with >95% Sensitivity * for WHO classification Ⅰ&Ⅱ (<10% of normal activity)
CareStart™ G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample.

More Less

Product category: Rapid tests - Immunochemistry

CareStart™ Malaria*

Features & Benefits

CareStart™ Malaria RDTs are rapid diagnostic tests that diagnose malaria infection from whole blood of patients in 20 minutes
Extensive lineup of 11 malaria RDT products targeting different combinations of Plasmodium parasites that cause malaria in humans, namely P. falciparum, P. vivax, P. malariae, P. ovale, as well as HRP2 deleted P. falciparum mutant malaria
Reliable test results with high sensitivity and specificity

More Less

Product category: Rapid tests - Immunochemistry

CareStart™ Dengue Combo (NS1+IgM/IgG)*

Dengue virus is transmitted by mosquitoes, and more than one-third of the world’s population is at risk for infection. Because there are no vaccines available to prevent infection with dengue virus, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

Features & Benefits

CareStart™ Dengue Combo (NS1 Ag+IgM/IgG) is a rapid diagnostic test that can simultaneously detect dengue virus in all clinical stages using both dengue NS1 antigen and anti-dengue antibodies (IgM/IgG) with one device.
Diagnosis of dengue infection from acute to convalescent stage
Detection of all four dengue serotypes from serum, plasma, or whole blood
True point-of-care test with no specimen preparation
Detecting All Clinical stage

More Less

Product category: Rapid tests - Immunochemistry

CareStart™ Scrub Typhus IgM*

Typhus fevers are caused by bacteria called O. tsutsugamushi and transmitted by arthropod (e.g. flea, mite, tick) bites. Scratching the bite opens the skin to the bacteria, allowing them to enter the bloodstream. Within the blood stream, the bacteria grow and replicate.

Features & Benefits

The CareStart™ Scrub Typhus IgM Test is intended for the qualitative detection of immunoglobulin M (IgM) to O.tsutsugamushi in serum, plasma, or whole blood.
User friendly
Fast and reliable

More Less

About us

Company details

Access Bio, a New Jersey based corporation formed in 2001 to develop, manufacture, and market in-vitro diagnostics tests worldwide. The Company utilizes advanced lateral flow technology for the production of point-of-care diagnostics to be sold to retail and the professional market. We have developed novel technologies for processing reagents and have produced these tests to meet FDA standards.

Access Bio plans to aggressively introduce other innovative rapid diagnostic products to the market. We focus on products which have significant market potential and high profit margin in the field of diagnostics (e.g., diabetes, cardiovascular disease, and neonatal diagnostics). A rapid gene chip product incorporating Peptide Nucleic Acid (PNA) technology, is being developed to detect specific genes or sequences associated with various disease indications. Proteomics technologies, which are not yet incorporated into any diagnostics products, are being used in our test development platform. There are currently no commercially available diagnostic products using proteomics technology. Our biochip line is presented as a rapid, one-step protein chip to detect multiple analytes and diagnose various diseases with a small volume of saliva, urine, serum, or whole blood. Assay results are converted to a digital signal off of the platform, which will enable quantitative results and communication of the test results between the point-of-test and medical experts through wireless or on-line technology. These products are used for both prognostic and diagnostic purposes.

More Less

Company data

Export content

> 75%

Number of employees




Area of business